Rosenstock J, Frias J, Jastreboff AM, Du Y, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet 2023 Jun 26:S0140-6736(23)01053-X. doi: 10.1016/S0140-6736(23)01053.
PMID: 37385280